C15454

C15454 is a small molecule agonist of the orexin 2 receptor (OX2R), identified as Example 484 in the patent WO 2019/027058. It was developed as a structurally distinct analogue of danavorexton (TAK-925) and has been utilized in preclinical research to evaluate the pharmacological targeting of the orexin system for sleep disorders. Orexin (hypocretin) signaling is a master regulator of arousal and wakefulness; agonists like C15454 are primarily investigated for the treatment of narcolepsy type 1, which is characterized by a deficiency in orexin-producing neurons. In preclinical studies using zebrafish larvae, C15454 demonstrated potent activity on both human and zebrafish orexin receptors, effectively increasing locomotor activity and reducing sleep-like behavior, confirming its functional conservation across species.